MIRA Pharmaceuticals starts MAD Phase 1 of oral Ketamir-2; selects CIPN for Phase 2a

MIRA PHARMACEUTICALS, INC.

Initiated multiple ascending dose (MAD) portion of Phase 1 trial for oral Ketamir-2 in healthy volunteers.
Selected chemotherapy-induced peripheral neuropathy (CIPN) as lead indication for planned Phase 2a study.
In SAD portion, no serious or dose-limiting adverse events; no clinically significant safety concerns.
Ketamir-2 is a non-scheduled oral analog of ketamine designed for once-daily dosing without psychoactive effects.
Preclinical data showed Ketamir-2 outperformed ketamine, gabapentin, and pregabalin in neuropathic pain models.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.